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Injury initiates recruitment of macrophages to support tissue repair; however, excessive macrophage activity may
exacerbate tissue damage causing further destruction and subsequent delay in wound repair. Here we show that
the peroxisome proliferation–activated receptor-g agonist, rosiglitazone (Rosi), a medication recently reintro-
duced as a drug to treat diabetes and with known anti-inflammatory properties, paradoxically generates pro-
inflammatory macrophages. This is observed in both IL-6-deficient mice and control wild-type mice experimen-
tally induced to produce high titers of auto-antibodies against IL-6, mimicking IL-6 deficiency in human diseases.
IL-6 deficiency when combined with Rosi-mediated upregulation of suppressor of cytokine signaling 3 leads to an
altered ratio of nuclear signal transducer and activator of transcription 3/NF-kB that allows hyper-induction of
inducible nitric oxide synthase (iNOS). Macrophages activated in this manner cause de novo tissue destruction,
recapitulating human chronic wounds, and can be reversed in vivo by recombinant IL-6, blocking macrophage
infiltration, or neutralizing iNOS. This study provides insight into an unanticipated paradoxical role of Rosi in
mediating hyper-inflammatory macrophage activation significant for diseases associated with IL-6 deficiency.
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INTRODUCTION
Suppressing inflammation often treats or prevents disease
progression in numerous destructive, degenerative, and auto-
immune conditions. Dysregulated inflammation may result in
prolonged macrophage activation and aberrant production of
pro-inflammatory cytokines resulting in damage to the sur-
rounding tissue (Akiyama et al., 2000; Pearson et al., 2003;
Fujiwara and Kobayashi, 2005; Hotchkiss and Nicholson,
2006). Rosiglitazone (Rosi), an insulin sensitizer, has recently
been revived by the Food and Drug Administration to treat
patients with type 2 diabetes mellitus, an indication similar to
other diabetes drugs currently available. Rosi belongs to the
thiazolidinedione class of drugs, which are ligands for the
nuclear hormone receptor peroxisome proliferation–activated
receptor-g (PPAR-g), and have been shown to attenuate
inflammation in experimental injury models (Park et al.,
2003; Cuzzocrea et al., 2004; Hasegawa-Moriyama et al.,
2012). Mechanistically, Rosi action on macrophages enhances
tissue repair by decreasing tumor necrosis factor (TNF)-a
and inducible nitric oxide synthase (iNOS) via induction of
suppressor of cytokine signaling (SOCS3), a negative regulator
of signal transducer and activator of transcription 3 (STAT3)-
dependent cytokine signaling (Jiang et al., 1998; Cuzzocrea
et al., 2004; Odegaard et al., 2007; Sener et al., 2007;
Chatterjee, 2010). SOCS3 expression is regulated by
IL-6, a pleiotropic acute-phase mediator with dual pro- and
anti-inflammatory effects (Xing et al., 1998; Li et al., 2012;
Tanaka and Kishimoto, 2012). Recently, we demonstrated
increased prevalence of impaired IL-6 signaling in people with
type 2 diabetes, as a result of IL-6 deficiency mediated by
development of auto-antibodies to IL-6 (aAB-IL6; Fosgerau
et al., 2010; Awazawa et al., 2011). We have shown that
generation of human-equivalent titers of aAB-IL-6 in mice
leads to impaired IL-6 signaling and impaired glucose
tolerance (Ciapponi et al., 1997; Galle et al., 2004; Puel
et al., 2008). As the primary indication of Rosi is in type-2
diabetics, we wanted to examine its anti-inflammatory effects
in the setting of impaired IL-6 signaling.
ORIGINAL ARTICLE
1Department of Dermatology, Case Western Reserve University, Cleveland,
Ohio, USA; 2Centre of Inflammation and Metabolism, Rigshospitalet, National
University Hospital, Copenhagen, Denmark; 3Department of Clinical
Immunology, Rigshospitalet, National University Hospital, Copenhagen,
Denmark; 4Department of Cellular and Molecular Medicine, Lerner Research
Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA and
5Department of Medicine, Medical College of Wisconsin, Milwaukee,
Wisconsin, USA
Correspondence: Kurt Q. Lu, Department of Dermatology, Case Western
Reserve University, 2109 Adelbert Road, BRB 529, Cleveland, Ohio 44106,
USA. E-mail: kurt.lu@case.edu
Received 5 November 2013; revised 22 May 2014; accepted 28 May 2014;
accepted article preview online 3 September 2014; published online 9
October 2014
Abbreviations: aABIL-6, auto-antibodies to IL-6; iNOS, inducible nitric oxide
synthase; LPS, lipopolysaccharide; NF-kB, nuclear factor kappa B; ODN,
oligodeoxyribonucleotide; PBS, phosphate-buffered saline; PPAR-g,
peroxisome proliferation–activated receptor gamma; pSTAT3, phosphorylated
signal transducer and activator of transcription 3; Rosi, rosiglitazone; SOCS3,
suppressor of cytokine signaling; TNF, tumor necrosis factor
& 2015 The Society for Investigative Dermatology www.jidonline.org 389
Our data show the effect of Rosi combined with IL-6
deficiency in vitro and in vivo results in generation of pro-
inflammatory iNOS-expressing macrophages via a SOCS3-
mediated altered nuclear STAT3/NF-kB ratio. Treatment with
Rosi of wild-type (WT) mice possessing high levels of aAB-IL-6
and IL-6 / mice resulted in drastic macrophage-mediated
de novo tissue destruction and delayed wound healing. The
data highlight a pivotal role of IL-6 deficiency in Rosi-
mediated activation and polarization of macrophages in an
experimental model system. Given the common co-occur-
rence of autoantibody-mediated IL-6 deficiency and usage of
thiazolidinedione medications, these findings may provide
insight into recent negative outcomes in subsets of diabetics.
RESULTS
Macrophage infiltration at the site of injury leads to tissue
destruction and delayed wound healing
We investigated the immune-modulatory effects of topical
Rosi on wound healing in IL-6 / mice using a skin injury
model. The use of a one-time low-dose UV exposure to a
clean surgical excision allows for exacerbation of inflamma-
tion through infiltration of activated macrophages to the
excision site. UV used in this model of inflammatory wounds
allows for accuracy in delivering a calibrated dose, thereby
minimizing inter-experimental variability. IL-6 / mice sub-
jected to the wound protocol demonstrate visible erythema in
regions between open wounds with little contraction com-
pared with WT. By day 9, WT mice progressed toward
resolution. In IL-6 / mice, however, the wounds remained
enlarged above baseline, ultimately requiring 23 days for
complete resolution (Figure 1a and b). When IL-6 / mice
were administered recombinant IL-6, the mice displayed
wound healing with resolution comparable to WT, validating
the critical role of IL-6 in this phenotype (Figure 1b).
Rosi induced an inflammatory response only in IL-6 / mice
subject to the inflammatory wound model and not in IL-6 /
or WT mice with surgical excision alone (no UVB;
Supplementary Figure 1a–d online).
Concurrent with delayed wound healing in IL-6 / mice
subjected to the wound protocol, we show histologically that
24 hours post treatment with Rosi, there is disruption of skin
architecture with epidermal erosion and underlying tissue
destruction that extended beyond the dermis (Figure 1c iso-
type control). As the immediate effect of skin injury is marked
by a massive infiltration of mononuclear cells especially
macrophages, we tested whether inhibiting macrophage entry
into the skin restores tissue morphology. Blocking with anti-
CD11b antibody in vivo has been previously shown to prevent
infiltration of monocytic cells into the skin (Hammerberg
et al., 1996; Qi et al., 2008). In our model, anti-CD11b-
treated IL-6 / mice demonstrated intact epidermis and
dermis with a sparse mononuclear infiltrate in the subcutis
(Figure 1c panel 2) compared with isotype control (Figure 1c
panel 3), which displayed epidermal necrosis, superficial
dermal necrosis, dermal edema, and a dense infiltrate of
inflammatory cells in the subcutis. Confocal microscopy
confirmed decreased macrophages (CD11bþ /F4/80þ cells)
in the skin of anti-CD11b-treated mice both in the dermis and
the subcutis (Figure 1d dermis panel 2, subcutaneous panel 2)
and demonstrated accelerated wound healing and full closure
by day 13 (Figure 1e).
To determine whether infiltrating monocytes are responsible
for the excess inflammation, we injected the skin of IL-6 /
mice with clodronate liposomes, a drug toxic to phagocytic
cells upon engulfment of the liposome. After 24 hours, the skin
at the wound edge from treated IL-6 / mice had normal
appearing epithelia with preservation of the epidermis and
dermis and sparse mononuclear cell infiltrates in the dermis
and subcutis (Figure 1f). In contrast, treatment with control
phosphate-buffered saline (PBS)-filled liposomes exhibited
dermal edema, epidermal necrosis, and superficial dermal
necrosis (Figure 1g). By 48 hours, the edema became massive,
whereas a drastic reduction in mononuclear cells was
observed in clodronate liposome–treated skin (Figure 1f
panel 2 vs. Figure 1g panel 2). On the basis of skin histology
and the ability of clodronate to accelerate wound healing, we
demonstrate that treatment with Rosi in this inflammatory
wound mouse model drives macrophage entry into the wound
to modulate inflammation and tissue destruction.
Hyper-inflammatory macrophages exacerbate iNOS-mediated
inflammation and delay wound healing at the site of injury
Activation of iNOS is well established in models of macro-
phage-mediated inflammation, and our data show that treat-
ment with Rosi of IL-6 / mice resulted in inflammation
associated with marked increase in iNOS mRNA levels from
the skin around the wounds at 12 hours that sustained for
24 hours (Figure 2a). No upregulation was observed in WT
mice. In both WT and IL-6 / mice, inflammatory infiltrates
were observed in histological sections mainly in the deeper
dermis and subcutis in the skin around the wounds (Figure 2b
panel 1, Figure 2c panel 1). Confocal microscopy of serial
sections shows that WT animals had low levels of iNOS
(Figure 2b panel 1) with macrophages staining CD11bþF4/
80þ but faintly for iNOS (indicated with white arrows),
whereas IL-6 / mice with same treatment condition show
robust staining for iNOS colocalizing with CD11bþF4/80þ
(marked with white arrows; Figure 2c panel 2). To determine a
role for iNOS in mediating delayed healing, IL-6 / mice
treated with the compound 1,400 W, a specific iNOS inhibitor
before wounding protocol, restored healing to 14 days
(Figure 2d), suggesting a role for iNOS. Mice subjected to
wound protocol were also given an i.p. injection of PBS as
vehicle control. In parallel studies, IL-6 / mice injected with
anti-TNF-a showed accelerated wound healing compared
with isotype-treated control mice (Supplementary Figure 2
online). Thus, IL-6 deficiency and Rosi treatment of mice drive
macrophage infiltration and activation (high iNOS and TNF-a)
toward a hyper-inflammatory state, propagating inflammation
and tissue destruction.
Mechanism of Rosi-mediated elevation of iNOS in macrophages
in the absence of IL-6
To appreciate a direct effect of Rosi on iNOS production
in vitro, IL-6 / and WT thioglycollate-elicited peritoneal
macrophages were dosed with Rosi. Treatment of IL-6 /
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Figure 1. Macrophage infiltration is necessary for delayed wound healing and tissue destruction. Wild-type and IL-6 / mice, subjected to wounding protocol,
are depicted (a) in images and (b) graphically (*1Po0.01, *2Po0.005, *3Po0.001, *4Po0.01, and *5Po0.05). Dotted line indicates ‘‘baseline’’ percentage of
wound area. Wound healing in the presence or absence of CD11b blocking antibody or isotype is shown by (c) hematoxylin and eosin (H&E) staining
(bar¼ 100mm), (d) confocal images of immunostaining for F4/80 (green), CD11b (red), and nucleus (blue), and (e) graphically. Wounds from IL-6 / mice were
injected intradermally with (f) clodronate liposomes and (g) control phosphate-buffered saline (PBS)-liposomes at 24 and 48 hours. Epidermal necrosis (*),
superficial dermal necrosis, dermal edema (**), and inflammatory cells in the subcutis (***) indicated. Box—epidermal–dermal junction. Arrow—wound edge.
Bar¼40mm.
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lipopolysaccharide (LPS)–primed macrophages caused marked
induction of iNOS mRNA compared with that in WT, which
remained at baseline (Supplementary Figure 3 online), sug-
gesting that Rosi treatment of macrophages initiates an
intracellular signaling cascade to promote transcription of
Nos2. However, using MAPPER that applies the recom-
mended stringencies of low E-values (o0.1) and high scores
(45), analysis of Nos2 showed no PPAR-g response elements
in the promoter region of the gene (Marinescu et al., 2005). In
addition, there is no direct link between PPAR-g and the major
transcription factor for iNOS, NF-kB (Ingenuity Pathways;
Pahan et al., 2001; Lawrence, 2009) reflecting potential
receptor-independent effects of Rosi on inflammation. As
PPAR-g ligands have been shown to induce SOCS3, we
hypothesized that SOCS3 has an indirect role in regulating
NF-kB activity in our wound model. Cytoplasmic SOCS3
inhibits phosphorylation of STAT3 and its subsequent nuclear
translocation (Qin et al., 2012). Nuclear STAT3 transrepresses
NF-kB, resulting in decreased iNOS expression (Yu et al.,
2002; Yu and Kone, 2004). We observed basal levels of
cytoplasmic SOCS3, reflective of a relative state of activation
resulting from thioglycollate elicitation of WT macrophages
(Figure 3a). SOCS3 was robustly increased in IL-6 / macro-
phages pretreated (16 hours) with Rosi in vitro followed by LPS
stimulation (15 minutes; Figure 3a lane 4). LPS priming of
IL-6 / and WT macrophages modestly increased cytoplasmic
phosphorylated STAT3 (pSTAT3) at 30 minutes (Figure 3b
lane 3). In contrast, Rosi pretreatment of IL-6 / LPS–primed
macrophages resulted in almost complete loss of cytoplasmic
pSTAT3 (correlating with high levels of SOCS3; Figure 3b
lane 5). Supplementation with recombinant IL-6 robustly
restored pSTAT3 in IL-6 / macrophages (Figure 3b lane 6).
Next, we determined whether Rosi-mediated decrease in
cytoplasmic pSTAT3 alters nuclear STAT3. In contrast to WT
macrophages treated with Rosi and LPS, IL-6 / macro-
phages had undetectable nuclear STAT3. These cells conco-
mitantly had robust increases in nuclear NF-kB (Figure 3c,
lane 4). Supplementation with recombinant IL-6 restored
nuclear STAT3 in IL-6 / macrophages, resulting in an NF-
kB/STAT3 profile and ratio similar to WT macrophages
(Figure 3b lane 5, 3c lane 5). In summary, the IL-6-deficient
condition where pronounced iNOS hyper-induction is
observed is one in which cytoplasmic SOCS3 is increased,
cytoplasmic-pSTAT3 is decreased, and nuclear STAT3 is
absent, resulting in a skewing of nuclear NF-kB/STAT3 ratios
(Figure 3a–d), thus defining the downstream biochemical steps
following Rosi treatment in WT versus IL6 / -activated
macrophages in vitro.
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Figure 2. Activation of infiltrated macrophages in the skin results in tissue destruction and delayed wound healing. (a) Quantification of inducible nitric oxide
synthase (iNOS) mRNA expression from the skin surrounding the wound edge of IL-6 / and control C57BL6 mice at indicated time points post rosiglitazone
(Rosi) treatment. Values are means±SE. *Po0.01, n¼ 3 mice. Hematoxylin and eosin stains of histological sections in (b) control and (c) IL-6 / skin. Confocal
images of skin sections from (b) C57BL6 mice and (c) IL-6 / mice after immunostaining for iNOS (blue) and CD11bþ (red) and F4/80þ (green) cells.
Bar¼40mm. (b, c) Arrows indicate co-localization of iNOS with macrophages in C57BL/6 and IL6 / section. (d) The wound healing capacity was measured in
Rosi-treated IL-6 / mice in the presence or absence of iNOS-specific inhibitor, 1,400 W. PBS, phosphate-buffered saline.
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As hyper-induction of iNOS was seen only in IL-6 /
macrophages, we next determined whether inhibition of
SOCS3 in these cells before Rosi and LPS treatment would
decrease iNOS expression. Transfection of bone marrow–
derived macrophages with a SOCS3-specific antisense oligo-
deoxyribonucleotide (ODN) resulted in transient knockdown
of SOCS3 (Supplementary Figure 4 online), restored cytoplas-
mic pSTAT3 expression at 30 minutes (Figure 4a), nuclear
STAT3 (Figure 4b) culminating in a 59% decrease in iNOS
expression (Figure 4c). The observations strengthen our find-
ings that Rosi treatment of macrophages sets off SOCS3
induction of iNOS by STAT3 in an IL6 -dependent manner.
Therefore, targeting STAT3 without Rosi should recapitulate
the effect mediated by Rosi treatment. IL-6 / macrophages
were transfected with a STAT3-consensus-binding-sequence
(STAT3 decoy). Independent of Rosi activation of macro-
phages, STAT3 decoy decreased nuclear STAT3 (Figure 4d),
resulting in a 2.4-fold increase in iNOS mRNA (Figure 4e).
Sense ODN served as control. Statistical comparisons demon-
strate that interfering specifically with STAT3 significantly
elevated iNOS compared with LPS alone or the ODN
control. Collectively, the in vitro data demonstrate that, in
an inflammatory response, Rosi treatment in IL-6 deficiency
initiates the PPAR-g-SOCS3-STAT3 signaling cascade that
modulates the expression of NF-kB and ultimately drives
iNOS expression.
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Figure 3. Increased suppressor of cytokine signaling 3 (SOCS3) regulates NF-jB-induction of inducible nitric oxide synthase (iNOS) in IL-6-deficient
macrophages. Peritoneal macrophages from IL-6 / and wild-type (WT) mice were pretreated with rosiglitazone (Rosi) for 16 hours and stimulated with
lipopolysaccharide (LPS) to detect (a) cytoplasmic SOCS3, (b) phospho-signal transducer and activator of transcription 3 (STAT3; n¼3 mice), (c) nuclear
localization of NF-kBp65 and STAT3 (n¼ 3 mice), and (d) the ratio of NF-kBp65 to STAT3 (n¼ 3, *P¼0.0021) with and without recombinant IL-6 (rIL-6). Open
bar graphs represent WT, and filled bars represent IL-6 / macrophages.
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Figure 4. Removal of suppressor of cytokine signaling 3 (SOCS3) allows nuclear translocation of signal transducer and activator of transcription 3 (STAT3) and
promotes inducible nitric oxide synthase expression in the absence of IL-6. Pretreated IL6 / bone marrow–derived macrophages (BMDMs) transfected with
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n¼ 5 mice, *P¼ 0.04, **P¼ 0.0148. NS, not significant; ODN, oligodeoxyribonucleotide.
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Rosi drives hyper-inflammation and tissue destruction in
autoantibody-mediated deficiency of IL-6
Next, we sought to determine the effect of Rosi in states of
physiologic IL-6 deficiency. We previously demonstrated that
aAB-IL-6 is measurable in 10% of Danish blood donors
with 0.1% of them producing high amounts of neutralizing
aAB-IL-6 (Hansen et al., 1991; Galle et al., 2004; Fosgerau
et al., 2010). To determine whether in vivo autoantibody-
mediated deficiency of IL-6 combined with Rosi would drive
hyper-inflammation and tissue destruction, we used a
vaccination protocol based on murine IL-6 analogs that
induces high titers of aAB-IL-6 (Ciapponi et al., 1997; Galle
et al., 2007). Control (C3HEN) and aAB-IL-6 mice were then
subjected to the previously described inflammatory wound
protocol with topical Rosi. By day 3, wounds in aAB-IL-6 mice
were enlarged with little contraction compared with controls.
By day 9, the wounds of C3HEN mice had progressed toward
resolution, whereas the wounds of the aAB-IL-6 mice
remained enlarged (Figure 5a and b). Strikingly, wound
closure was delayed by 5 days in these mice compared with
controls (Figure 5b). At 24 hours, wound areas of aAB-IL-6
mice were 50% larger compared with initial wound size
(Figure 5a and b), which corresponded to a significant
increase in iNOS relative mRNA expression (Figure 5c) from
skin biopsies obtained from the wound. Thus, iNOS induction
of aAB-IL-6-induced mice is reminiscent of high iNOS levels
in IL-6 / mice subject to our treatment protocol (Figure 2a)
and supports our hypothesis that the observed paradoxical
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hyper-inflammatory effect of Rosi is due to a deficiency in IL-6
and its signaling.
DISCUSSION
The thiazolidinedione class of drugs have previously been
shown to be anti-inflammatory and capable of generating
alternatively activated macrophages that function to attenuate
inflammatory mediators like iNOS and COX2 (Jiang et al.,
1998; Ricote et al., 1998; Feinstein et al., 2005; Hasegawa-
Moriyama et al., 2012); however, our data show a deviation
from the anti-inflammatory response to this medication. We
demonstrate that the net response of Rosi treatment and
concomitant IL-6 deficiency is a paradoxical exacerbation of
inflammation. Rosi in this capacity may be acting through the
PPAR-g receptor but may also have receptor-independent
effects. Direct evidence for PPAR-g-independent effects
comes from studies in which PPAR-g antagonists were
unable to block anti-inflammatory actions in LPS-stimulated
cells, and PPAR-g deficiency did not affect Rosi (and
pioglitazone)-mediated production of prostaglandin
(Tsukamoto et al., 2004; Feinstein et al., 2005). Moreover,
Rosi inhibited iNOS function in activated macrophages at a
concentration 650-fold higher than its EC-50 value for
binding PPAR-g, indicative of multiple effects of Rosi on the
cell beyond receptor-mediated signaling (Ricote et al., 1998).
Our data show that Rosi increases SOCS3, transiently altering
the nuclear STAT3/NF-kB ratio by decreasing STAT3
translocation into the nucleus. Decreased nuclear accumulation
of STAT3 regulates the expression of NF-kB-responsive
genes such as iNOS, via reduced transrepression of NF-kB
(Figure 6a and b; Yu et al., 2002; Park et al., 2003; Yu and
Kone, 2004).
Hyper-inflammation is attenuated by endogenous inhibitors
of pro-inflammatory cytokines such as soluble TNF-a receptor
that helps regulate and limit inflammatory signals (Tilg et al.,
1994; Sikora et al., 2008, 2009). Concurrent with other studies
(Tilg et al., 1994), examination of peritoneal fluid of
thioglycollate-activated aAB-IL-6 mice showed significantly
less secretion of soluble TNF-a receptor (Supplementary
Figure 5 online). Thus, a limited capacity to downregulate
extracellular cytokine stimulation in IL-6 deficiency combined
with decreased NF-kB transrepression via Rosi results in
hyper-inflammation. As SOCS3 and STAT3 form a regulatory
feedback loop, these alterations represent a transient escape
from regulated inflammatory responses resulting in hyper-
inflammation. The parallels of both the in vivo and in vitro
studies demonstrate that indeed Rosi and IL-6 deficiency
together show paradoxical hyper-activation of macrophage.
Taken together, the model of delayed wound healing proposed
requires Rosi/SOCS3 induction of iNOS via increased NF-kB
activation coupled to decreased transrepression of NF-kB
culminating in excessive inflammation and tissue destruction
(Figure 6a and b). Although we tested the contribution of
hyper-activated macrophages that prolong inflammation and
delay wound healing in our Rosi study model, our findings
may be relevant to other cell types that populate the wound
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prevents nuclear translocation of activated STAT3 resulting in loss of NF-kB transrepression. The net result of decreased NF-kB transrepression and simultaneous
increased NF-kB activity via TNF-a and other pro-inflammatory cytokines drives increased iNOS expression and subsequent tissue damage.
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bed after tissue injury. Infiltrating neutrophils are a source of
iNOS that may contribute to damage of surrounding tissue
(Tsukahara et al., 2001). In this model, we speculate that
neutrophils enhance the chemoattraction for macrophages into
the wound bed but are not the critical cellular source of iNOS
at later stages of the tissue destruction. Subsets of dendritic
cells, specifically plasmacytoid dendritic cells, have an
important role in wound healing. In response to nucleic
acids from cellular debris, plasmacytoid dendritic cells
secrete type-1 IFNs to accelerate wound healing through
reepithelialization of injured skin (Gregorio et al., 2010). As
DC function is affected by PPAR-g ligands (Faveeuw et al.,
2000; Hammad et al., 2004), it is unclear in the IL-6-deficient
system whether there is diminished type-1 IFN produc-
tion, thereby indirectly contributing to delayed wound repair.
In our IL-6-deficient skin injury model, treatment with Rosi
may set off a similar influx of immune cells populating the
wound, but the accumulation and activation of iNOS-
producing macrophages may outnumber other cell types and
impart a lasting and profound effect on the progression of
inflammation.
These findings may be germane to wound healing and
destructive inflammation in other organ systems. In addition, it
will be of interest to determine whether a patient population
showing auto-anti-IL6 antibodies will demonstrate elevated
levels of iNOS in inflamed tissue. As there are other iNOS-
responsive cells (Curran et al., 1989; Campanholle et al.,
2010; Harbrecht et al., 2012; Lowry et al., 2013; Mao et al.,
2013; Wheeler et al., 2013), this mechanism of hyper-
induction of inflammation may be a common physiological
response in mediating tissue destruction in other organs. The
association of a paradoxical hyper-inflammatory state with
Rosi and IL-6 deficiency provides insight into the cellular basis
for clinical situations of non-resolving or exacerbated
inflammation. aAB-IL-6 occurs naturally in 2–10% of the
European and Japanese general population (Hansen et al.,
1991; Takemura et al., 1992; Galle et al., 2004), which
increases with age, and recently shown to be more common
in patients with rheumatic disease and type 2 diabetes
(Fosgerau et al., 2010). The combination of an injurious
event in an aAB-IL-6 patient taking Rosi medication may
result in hyper-inflammation. Therefore, screening for aAB-IL-
6 in humans may have predictive value for preventing
potential adverse effects of thiazolidinedione treatment
therapies. In addition, the clinical scenario in which Rosi
treatment coincides with IL-6 deficiency is not limited to
prescribed medications as activation of PPAR-g can result
from many endogenous ligands such as oxidized lipids
(Chomarat et al., 2000; Liu et al., 2012; Nagy et al., 1998).
With the widespread use of thiazolidinedione drugs
prescribed for diabetes, several reports of unexplained
increased edema and also increased fatal cardiac events
with Rosi in diabetics (Rosen, 2007) raise the suspicion of
hyper-inflammatory responses as a factor in these adverse
outcomes. Furthermore, activated macrophages and
exacerbated inflammation are known to contribute to the
cardiovascular disease pathogenesis (Hansson, 2005). In
conclusion, research designed to target hyper-inflammatory
macrophages will likely improve the ability to treat chronic
wounds and allow for development of a previously unreported
therapeutic approach to other chronic conditions.
MATERIALS AND METHODS
Mice
Pathogen-free, 6- to 8-week-old female WT and IL-6 / C57BL/6J
mice were obtained from Jackson Laboratories (Bar Harbor, ME).
Three- to four-week-old female C3HHeN mice were obtained from
Harlan Industries. The animal studies have been approved by the
Institutional Animal Care and Use Committee at Case Western
Reserve University.
Immunofluorescence
Macrophages were defined as cells that stained positive for F4/80 and
CD11b. For immunofluorescence staining of skin, 8mm sections of
frozen tissue were sectioned and fixed in 4 1C 100% acetone for
10 minutes. For immunofluorescence of lung tissue, 5mm sections
were fixed in formalin, embedded in paraffin, and deparaffinized in
xylene and ethanol. Primary and secondary antibodies were diluted
as indicated in 1 PBS: anti-mouse F4/80 Antigen Alexa-488 BM8
(eBioscience, San Diego, CA, 1:100); rat monoclonal (M1/70) to
CD11b APC/Cy7 (Abcam, Cambridge, MA, 1:20); and rabbit anti-
iNOS/iNOS II, NT (Millipore, Billerica, MA, 1:50).
Reverse transcriptase–PCR
For reverse transcriptase–PCR analysis, RNA was isolated using Trizol
(Invitrogen, Carlsbad, CA), following the manufacturer’s instructions,
and was reverse-transcribed and quantified using the Applied Biosys-
tems TaqMan RNA-to-CT 1-Step Kit, TaqMan Gene Expression Assays
for 18s RNA, iNOS, TNF-a, and the Step-One System. Cycle time,
temperature, and number were based on Applied Biosystems
(Grand Island, NY) recommendations.
Wound preparation, treatment, and measurement
The skin was wounded as described. After shaving and chemical
depilation of hair from the dorsal back skin, mice were allowed to rest
for 48 hours. Using a template to mark out three circles of 6 mm
diameter spaced apart in an equilateral triangle on dorsal skin, mice
were subject to three excisional biopsies. Three wounds were chosen
to capture variations in innate healing rates in each individual animal.
To exacerbate inflammation in these clean surgical excisions, we
exposed the wounds to a one-time single low dose of 72 mJ cm 2
UVB, a dose previously shown to enhance infiltration of monocytes
and macrophages into the skin without inciting further injury
(Baadsgaard et al., 1987; Meunier et al., 1995). At day 0, wounds
were measured lengthwise and widthwise, exposed to 1 minimal
erythema dose UVB, and treated topically with a 1% solution of Rosi
in 10 g Aquaphor (Beiersdorf, Wilton, CT). Wounds were measured
and topical Rosi solution applied daily until healed (loss of serum
crust and reepithelialization).
Peritoneal macrophages
Mice were injected i.p. with 2 ml of thioglycollate and killed 24 hours
later by cervical dislocation. Lavage was performed by infusing 5 ml
of 4 1C Dulbecco’s phosphate buffered saline into the peritoneal
cavity. The fluid sample is recovered by aspirating the liquid with a
syringe. A volume of 80%±21% of instilled fluid is recovered.
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Bone marrow–derived macrophages
Briefly, bone marrow cells were flushed aseptically with PBS from the
dissected femurs of mice. The cells were cultured on 25 cm2 plates in
DMEM containing 15% fetal calf serum, 1% penicillin/streptomycin,
1% L-glutamine, 4.5 g l 1 glucose, and 20mg l 1 macrophage colony
stimulating factor. After 6 days, media were changed to remove any
cellular debris and non-adherent cells. The following day (day 7), the
cells were carefully removed using lidocaine (4 mg ml 1) and 10 mM
EDTA in PBS at pH 7.5 and dispensed into six-well plates at a
concentration of 2 106 cells per well. Before experimentation,
media were replaced with macrophage colony stimulating factor-free
media containing 5 mM L-arginine.
Western blot
The NE-PER kit (Thermo Scientific, Waltham, MA) was used to extract
nuclear and cytoplasmic protein from peritoneal macrophages.
Protein samples were prepared under reducing conditions, and
western blot analysis was performed using a standard protocol
(Invitrogen). Stat3 (79D7), NF-kB p65, and b-actin (13E5) rabbit
mAbs (Cell Signaling Technology, Danvers, MA) were used for
detection. Western blots were analyzed by densitometric scanning
of immunoblots by the Biorad VersaDoc imaging system (Bio-Rad,
Hercules, CA).
Transfection of STAT3 decoy and mismatched
oligodeoxyribonucleotides
Phosphorothioated ODNs used for STAT3 decoys were purchased
from Sigma-Genosys Biotechnologies (The Woodlands, TX). The
decoy sequences, 50-GATCCTTCTGGGAATTCCTAGATC-30 and
30-CTAGGAAGACCCTTAAGGATCTAG-50 for the Stat3 decoy and
50-GATCCTTCTGGGCCGTCCTAGATC-30 and 30-CTAGGAAGACCC
GGCAGGATCTAG-50 for the mismatched STAT3 decoy, were used
in published studies (Xu et al., 2003). Single-stranded ODNs were
annealed by incubation at 65 1C for 10 minutes and then cooled to
room temperature for 2 hours. Double-stranded decoys were
transfected into monocytes 24 hours before stimulation at a final
concentration of 2mM by using Superfect (Qiagen, Valencia, CA)
following the manufacturer’s instruction.
Treatment with sense/scrambled and antisense
oligodeoxyribonucleotides for SOCS3
The antisense ODN sequences for SOCS3 were selected from
published literature (Lovibond et al., 2003). Control ODNs for
SOCS3 consisted of complementary sense ODNs. All ODNs were
end modified (three bases of 50 and 30 ends phosphorothioated) to
limit DNA degradation, and all were HPLC-purified pre-use
(Invitrogen). Macrophages (5 106 cells per well) were plated in
six-well culture plates overnight. Cells were then transfected with
SOCS3 sense and antisense ODNs at 2mM concentration using Mirus
TransIt-Oligo Transfection Reagent (Mirus Bio, Madison, WI)
according to the manufacturer’s protocols, and the incubation was
continued for 24 hours. For the transfection control, monocytes were
incubated with the transfection reagent alone.
Antibodies and reagents
A total of 1,400 W (Sigma, St Louis, MO) was given at a 10mg g 1
dose. STAT3 cell-permeable peptide and inactive control (EMD
Chemicals, Billerica, MA) were used at 5mM final concentrations.
Rosi (Alexis Biochemical, Farmingdale, NY) was used at a 5mM final
concentration for in vitro experiments, and at 0.2 mg per mouse for
i.p. injections. ELISAs for soluble TNF-a receptor were performed
according to the manufacturer’s specifications (R&D Systems, Min-
neapolis, MN). Phospho-Stat3 (Tyr705) (D3A7) rabbit mAb were
obtained from Cell Signaling (Beverly, MA) and PPAR-g (E-8) sc-7273
from Santa Cruz (Dallas, TX).
Cloning, expression, and purification of mIL-6 analogs and
vaccine production
IL-6 analog vaccine was developed as previously described (Galle
et al., 2007). Briefly, wt mIL-6 were expressed in E. coli and purified
by Ni-NTA affinity chromatography (Qiagen Nordic, Sverige,
Denmark). Purity was assured by SDS-PAGEs. The analogs were
adsorbed to Al(OH)3 (Alhydrogel 1.3% Brenntag Biosector AIS,
Frederikssund, Denmark) in accordance with the manufacturer’s
instructions. After Al(OH)3 adsorption, the mixture was washed
three times in 0.9% (w/v) NaCl and finally suspended in 0.9%
NaCl at a concentration of 39mg per 100ml suspension. The vaccines
were stored at 4 1C.
Vaccine protocol
Mice were vaccinated subcutaneously on the dorsal side. Vaccina-
tions were performed on days 0, 21, 42, and 63. Levels of plasma
aAB-IL-6 were assessed by radio-immunoassay 14 days after each
vaccination (Galle et al., 2007). Blood samples were collected from
the tail vein.
Statistical analysis
Data presented as meansþ SE. P values were calculated using a two-
tailed Student’s t-test for two samples of unequal variance. Statistical
significance is indicated by an asterisk, and P values reported in figure
legends.
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